Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(tested or 100% immunogen sequence identity)
Protein A/G purified
Complement C5 antibody was raised against c5 isolated from human plasma.
Specific for human C5. No reaction is seen with plasma from patients deficient in C5. Epitope specificity differs from that of clone 6F72 but overlaps slightly as determined by inhibition ELISA. Reacts strongly with C5. Strong reaction is seen with normal human plasma, and no reaction is seen with plasma from patients deficient in C5, when tested in sandwich ELISA in combination with a polyclonal antibody against C5. In Western blotting after SDS-PAGE this antibody reacts with C5 in normal human plasma (PEG precipitated C5) in nonreduced form only. No reaction is seen with plasma from C5 deficient patients.
Suitable for use in ELISA, Western Blot. ELISA: 1:8000.
PBS, pH 7.4, 15 mM Sodium Azide
Short term: 4°C. Long term: Store at -20°C. Avoid freeze-thaw cycles.
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process.